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IN a previous communication to this journal (Harper, 1957) an investigation
of the metabolic end products of pyrene following intravenous and intraperi-
toneal injections in the mouse and the rat was reported. These end products
appeared in the urine and/or the faeces and were identified as: 3-hydroxypyrene,
mainly free but possibly conjugated to a small extent, pyrene-3: 8- and 3: 10-
quinones, and 3: 8- and 3: 10-dihydroxypyrenes mainly conjugated. In addition
evidence was obtained of the presence of an acid-decomposable pyrene precursor
and anunidentified " quinonoidal complex " which liberated freepyrene on heating
with hydrochloric acid.
This work has now been extended to cover metabolism within the tissues and
a report of the results and conclusions is given here.
MATERIALS AND METHODS
Throughout these experiments mice of RIII, Strong A, C.B.A. and Swiss
strains were used and it is perhaps worthy of note that the same metabolic
behaviour has been observed in all four strains.
The pyrene was prepared for injection as a fine colloidal dispersion containing
1 mg. per c.c. by dissolving 100 mg. in the smallest possible volume ofacetone and
injecting the acetone solution beneath the surface of 100 c.c. distilled water.
The acetone was then removed from the resulting colloid under reduced pressure.
Each mouse received an intravenous injection of 0-5 c.c of the colloid. The
animals in batches of 10 to 20 were then killed at intervals of 12 to 2-1 hours
following the injection and the particular organ under consideration quickly
dissected out and extracted immediately.
Based upon the isolation procedure devised for the intermediary metabolites
of 3: 4-benzpyrene by Weigert and Mottram (1946) and upon the properties of
the pyrene derivative first isolated from the bile, the following general extraction
procedure was adopted.
The organs were homogenised in a Waring blender, extracted with 70 per cent
acetone and filtered. The acetone was then pumped off under reduced pressure
and the residual aqueous phase saturated with ammonium sulphate and acidified
with hydrochloric acid. Extraction with ether was then carried out until no
appreciable fluorescent material was removed. The ether extract was dried with
sodium sulphate, mixed with an equal volume of benzene and the ether removed
from the mixture under reduced pressure. The benzene, approximately 200
c.c. in volume, was then chromatographed on columns ofsilica gel (100/200 mesh)INTERMEDIARY METABOLISM OF PYRENE
over alumina. These were best prepared by the slurry technique and separation
of the two adsorbents was effected by the interposition of discs of filter paper.
Small chromatography tubes were generally used, of internal diameter 14 mm.
and length 16*5 cm. and contained approximately equal lengths of the two
adsorbents.
RESULTS
(a) Gall bladder.-The bile possessed a strong blue fluorescence in ultraviolet
light and for extraction purposes it was diluted with several volumes of distilled
water.
An ether extract of the diluted bile showed a weak blue fluorescence and con-
tained only a trace amount offree pyrene. After acidification with hydrochloric
acid however, a further ether extract was yellow in colour and possessed a strong
blue/violet fluorescence. Spectroscopic examination suggested that this was due
to the presence of a pyrene derivative with its adsorption maxima displaced to
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FIG. 1.-Absorption spectra in ethyl alcohol. 1. 3-Hydroxypyrene
glucuronide conjugate. 2. PX.
shorter wavelengths relative to those of 3-hydroxypyrene. The ether extract was
transferred to benzene which was then chromatographed on silica gel over alumina
as described above. Examination of the chromatogram under ultraviolet light
revealed the presence of a diffuse dull blue/violet zone extending downwards
from the surface of the silica gel. This, when eluted with ethyl alcohol, gave a
blue/violet fluorescent solution with the pyrene type spectrum referred to above.
As eluted from the silica, however, it appeared to be associated with a certain
amount of yellow colouring matter. It was finally obtained free from this by
evaporating a solution in slightly moist ether to dryness and washing the residue
with several small volumes of benzene. The residue, dissolved in ethyl alcohol,
was colourless and possessed the absorption spectrum shown in Fig. 1 with
maxima at 234, 242, 255, 265, 276, 328, 342, 359-60, 371 and 380 m,u.
The new derivative was readily soluble in water and on warming with dilute
hydrochloric acid was rapidly converted into 3-hydroxypyrene.
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With naphthoresorcinol reagent it gave a weak positive test for glucuronic
acid.
In view of these properties allied with the close spectral similarity to 3-
hydroxypyrene it appeared likely that the derivative was a glucuronide conjugate
of 3-hydroxypyrene. This was verified by incubation at 370 C. with ,5-glucuroni-
dase (bacterial) at pH 7 when cleavage of the glucosiduronic acid rapidly took
place resulting in the formation of pure 3-hydroxypyrene.
(b) Duodenum and small intestine.-Spectroscopic examination of the ether
phase during the extraction procedure suggested the presence of a considerable
amount of the 3-hydroxypyrene glucuronide conjugate and this was confirmed
on analysis of the silica gel chromatogram. In addition a small amount of free
3-hydroxypyrene was identified on the alumina.
(c) Caecum and large intestine.-Analysis of the chromatogram from these
tissues revealed that the major metabolite was now 3-hydroxypyrene and that
only a small amount of the glucosiduronic acid was present.
(d) Bladder.-Extraction ofthe urine with ether at pH 7 resulted in theremoval
of a small amount of free 3-hydroxypyrene. On adjusting the pH of the urine
to pH 2, however, a considerable amount of the 3-hydroxypyrene glucuronide
conjugate was extractable with ether.
(e) Kidney.-The fluorescence of the extract from this tissue was much
reduced in intensity compared with that from the gut. Analysis ofthe chromato-
gram revealed that a small amount of the glucosiduronic acid and a trace amount
of 3-hydroxypyrene were present.
(f) Liver.-Contrary to expectations neither the glucosiduronic acid nor the
free phenol were extractable from this tissue. Instead however, on elution with
ethyl alcohol, the silica gel yielded a straw coloured, weak blue fluorescent solution.
This eluate, on spectroscopic examination, was found to possess a pyrene type
spectrum with maxima at 232, 242, 264, 275, 310, 324-25, 340-41 and 376 mp.
A purer sample (spectrum Fig. 1) was obtained by direct chromatography on
alimina when the derivative, symbolised as PX, was held as a narrow zone at the
surface. The appearance ofthe spectrum in the lower wavelengths suggested the
presence of strongly absorbing background material but attempts to remove
such material were unsuccessful.
When a solution of the PX in ethyl alcohol was acidified with hydrochloric
acid the fluorescence rapidly changed to blue/violet and on heating the mixture
the PX was converted into 3-hydroxypyrene. The same transformation was effec-
ted by incubationi with ,-glucuronidase so it is possible that a ,-glucosiduronic
linkage is present in the molecule. The general behaviour of this compound
was therefore in keeping with it being a glucuronide conjugate of an unstable
pyrene diol, but the spectroscopic evidence did not support this view.
The site ofmetabolism
In an attempt to determine the site ofmetabolism within the animal incubation
experiments were carried out with liver and kidney slices. The slices were incu-
bated at 370 C. for 3 hours in Tyrode solution containing 0.1 mg. colloidal pyrene
per c.c., oxygen being bubbled through the solution to ensure adequate aerobic
conditions. The slices were then subjected to the extraction procedure used for
the in vivo experiments.
Liver slices. The slices assumed a distinct blue/violet fluorescence and on
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extraction the unidentified PX, 3-hydroxypyrene and the 3-hydroxypyrene
glucuronide conjugate were identified.
Kidney slices.-The fluorescence of the slices remained unaltered and on
extraction no evidence of metabolism was obtained.
DISCUSSION
In view of the fact that PX is the only metabolite extractable from the liver
of the intact animal whereas the free phenol and the phenol glucuronide conjugate
are obtained in addition to PX from liver slice incubation experiments, it appears
likely that PX is the primary metabolite formed during the metabolic oxidation
of pyrene to 3-hydroxypyrene. These experiments suggest that the PX is con-
verted into the 3-hydroxypyrene glucuronide conjugate in the liver and that
the latter is then immediately removed in the bile or transported to the kidney
and eliminated in the urine. The hydrolytic cleavage of the glucuronide con-
jugate to the free phenol which then takes place, either during passage through
the caecum and large intestine or during storage in the bladder, must be attributed
to enzymatic activity as the glucuronide is only slowly decomposed by acid at
370 C.
Support for these conclusions is provided by the established presence of
,/-glucuronidase in the urine and by the findings of Marsh, Alexander and Levvy
(1952) who determined the sites ofglucuronide decomposition down the digestive
tract of various animal species. Unfortunately the mouse was not included
but in the rat, which yields the same metabolites ofpyrene as the mouse (Harper,
1957) the concentration of glucuronide decomposing enzymes in the caecum and
colon relative to that in the duodenum and ileum was approximately 30: 1. In
the rabbit the ratio was even higher, being 180: 1.
The absence ofthe quinones inthe large intestine suggeststhatthese are formed
as oxidation products ofthe 3-hydroxypyrene after excretion in the faeces.
In view of the finding that the urine obtained from the dissected bladder
contained principallytheglucuronide conjugate the apparent anomalous behaviour
previously observed with 24 hour urine specimens can now be explained. It was
found that after continuous Soxhlet extraction with ether at pH 6 to remove
free phenol,the 24hour urinesampleryieldedafurtheramount of3-hydroxypyrene
during extraction with ether at pH 2, this being most marked in the case of the
mouse (Harper, 1957). This can now be attributed to the hydrolysis of the glu-
curonide conjugate during the warm acidic conditions prevailing in the Soxhlet
apparatus. Failure to obtain glucuronide conjugate as such from the urine has
now been shown to be due to the isolation procedure adopted as the glucuronide
is strongly adsorbed on alumina from benzene and cannot be eluted with ethyl
alcohol. It can be eluted, however, if a smnall amount of hydrochloric acid is
added to the alcohol.
Although providing a satisfactory explanation for the final elimination of
free 3-hydroxypyrene in both urine and faeces these experiments have yielded
no evidence concerning the presence of dihydroxy compounds in the urine. No
trace ofthese compounds or possible metabolic precursors has been obtained from
the tissues examined so it is possible that they, like the quinones, are formed as
secondary oxidation products from 3-hydroxypyrene. This problem is to receive
further investigation.
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SUMMARY
(1) Evidence has been obtained that the metabolic oxidation of pyrene to
3-hydroxypyrene proceeds via two intermediate stages.
(2) The experiments suggest that a primary metabolite, symbolised as PX,
is formed in the liver and that this is converted into the glucuronide conjugate
of 3-hydroxypyrene which is excreted in the bile and urine.
(3) During storage in the bladder or passage through the caecum and large
intestine the glucuronide conjugate is then enzymatically hydrolysed to free
phenol.
(4) The nature ofthe metabolite PX has not yet been determined.
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